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Abstract
Background: Long non-coding RNAs (lncRNAs) have been confirmed to be involved in the pathologi-
cal processes of multiple diseases. However, the characteristic expression of lncRNAs in peripheral blood 
of coronary artery disease (CAD) patients and whether some of these lncRNAs can be used as diagnostic 
biomarkers for CAD requires further investigation. 
Methods: Six healthy and CAD individuals were selected for microarray analysis, and 5 differentially 
expressed lncRNAs were selected and confirmed in the second cohort consisting of 30 control individu-
als and 30 CAD patients with different SYNTAX scores. Upperhand were verified in the third cohort 
consisting of 115 controls and 137 CAD patients. 
Results: Thirty one lncRNAs were differentially expressed between the two groups, among whom,  
25 were upregulated in the CAD group and 6 were downregulated. Four of the selected five lncRNAs were  
significantly upregulated in the CAD group, and Upperhand had the largest area under the curve (AUC). 
The diagnostic value of Upperhand was tested further, and it remained having a high diagnostic value.
Conclusions: The expression level of Upperhand in peripheral blood of CAD patients is significantly 
higher than in control individuals, and is correlated with severity of CAD. Upperhand is a potential 
diagnostic biomarker of CAD, and when combined with TCONS_00029157, diagnostic value slightly 
increased. (Cardiol J 2018; 25, 3: 393–402)
Key words: coronary artery disease, long non-coding RNA, microarray analysis,  
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Introduction
Coronary artery disease (CAD) has a significant 
impact on public health. According to a 2014 statis-
tical summary by the World Health Organization 
(WHO), cardiovascular diseases are the most lethal 
non-communicable diseases worldwide in 2012, 
accounting for 46%. Although there are standard 
treatments for CAD at present, such as drug therapy, 
percutaneous coronary intervention (PCI) and coro-
nary artery bypass graft (CABG) surgery, the prog-
nosis is still not satisfactory for some patients [1, 2]. 
This discrepancy is mainly because the current 
diagnostic methods cannot achieve high accuracy 
and convenience at the same time, which obviously 
increases the missed diagnosis rate. Therefore, 
a new highly sensitive and convenient diagnostic 
biomarker of CAD would be of great value.
In the past, non-coding RNAs had been con-
sidered the “dark matter” in the genome because 
of their indefinite types and functions. However, 
increasing evidence has demonstrated that though 
non-coding RNAs do not code for proteins directly, 
they do play important regulatory roles in the 
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transcription and translation of protein-coding 
genes. Long non-coding RNA (lncRNA) is one 
important type of non-coding RNAs with a length 
greater than 200 nucleotides. LncRNAs are able 
to regulate gene expression through multiple 
approaches, including transcriptional regulation, 
post-transcriptional regulation and regulation 
of pre-mRNA splicing. In a word, lncRNAs have 
a broad range of biological functions [3–7].
LncRNAs have been confirmed to be inti-
mately involved in various diseases, such as Alz-
heimer’s disease, schizophrenia, diabetes mel-
litus, cancer [8–12]. Lu et al. [13] found that 
lncRNA H19 can be used as a biomarker for the 
early diagnosis of gastric cancer. de Kok et al. 
[14] revealed that lncRNA PCA3 in urine can 
be applied to diagnose prostate cancer, with 
a higher specificity than the prostate-specific anti-
gen (PSA) test which is now widely used in clinics. 
Xie et al. [15] indicated that lncRNA HULC can 
be utilized to diagnose hepatocellular carcinoma. 
In cardiovascular diseases, lncRNAs have also 
been verified to be involved in the pathological 
process of heart failure, myocardial infarction, di-
lated cardiomyopathy and coronary atherosclerosis 
[16–22]. Kumarswamy et al. [17], found, with the 
use of microarray analysis, that lncRNA-LIPCAR 
was substantially negatively related to left ventric-
ular remodeling; the expression level of LIPCAR 
was positively associated with mortality of patients 
with systolic heart failure was also verified. Chro-
mosome 9p21 contains a lot of CAD related single 
nucleotide polymorphisms, one of which is overlap-
ping with antisense noncoding RNA in the INK4 
locus (ANRIL). ANRIL expresses in many CAD 
related tissues and cells, such as coronary artery 
smooth muscle cells, vascular endothelial cells and 
atherosclerotic plaques [23]. In the present study, 
the peripheral blood lncRNA profiles between con-
trol individuals were compared and matched with 
CAD patients by microarray analysis, the findings 
were then tested in larger independent cohorts.
Methods
Study population
This study included a total of 324 participants, 
all of whom were enrolled from outpatients and 
inpatients of the Department of Cardiology of the 
People’s Hospital of Zhengzhou University from 
July 2015 to June 2016. This study had a total 
of three cohorts (their clinical and demographic 
characteristics are shown in Tables 1–3). Subjects 
with any of the following characteristics were ex-
cluded: (i) malignant tumors, (ii) hepatic or renal 
dysfunction, (iii) any other clinically systemic acute 
Table 1. The clinical and demographic  
characteristics of the first cohort. 
Control  
group
CAD  
group
P
Male gender 3 (50%) 3 (50%) 1
Age [years] 60 ± 2.3 61.7 ± 7.9 0.629
Hypertension 1 (16.7%) 2 (33.3%) 1
Diabetes mellitus 0 0 1
Smoker 1 (16.7%) 1 (16.7%) 1
HbA1c [%] 5.4 ± 0.1 5.4 ± 0.2 0.585
TC [mmol/L] 3.5 ± 0.9 4.2 ± 0.9 0.179
TG [mmol/L] 0.9 ± 0.2 1.1 ± 0.4 0.315
HDL [mmol/L] 1.3 ± 0.3 1.0 ± 0.2 0.061
LDL [mmol/L] 1.8 ± 0.7 2.1 ± 0.5 0.355
ALT [U/L] 36.3 ± 17.8 30.0 ± 11.8 0.485
AST [U/L] 23.5 ± 3.8 28.3 ± 10.0 0.293
Scr [μmol/L] 58.7 ± 3.9 67.0 ± 7.0 0.029
FT4I [pmol/L] 14.4 ± 2.7 15.0 ± 1.1 0.629
CAD — coronary artery disease; TC — total cholesterol; TG — tri­
glyceride; HDL — high density lipoprotein; LDL — low density lipo­
protein; ALT — alanine transaminase; AST — aspartate transamin­
ase; Scr — serum creatinine, FT4I — free thyroxine index
Table 2. The clinical and demographic  
characteristics of the second cohort.
Control  
group
CAD  
group
P
Male gender 12 (40%) 17 (56.7%) 0.301
Age [years] 57.3 ± 7.5 59.3 ± 7.1 0.284
Hypertension 10 (33.3%) 16 (53.3%) 0.193
Diabetes mellitus 7 (23.3%) 13 (43.3%) 0.171
Smoker 8 (26.7%) 12 (40%) 0.411
HbA1c [%] 5.4 (5.0, 5.7) 5.6 (5.3, 6.3) 0.187
TC [mmol/L] 4.0 ± 0.7 4.4 ± 0.8 0.057
TG [mmol/L] 1.9 ± 0.8 1.7 ± 0.6 0.231
HDL [mmol/L] 1.0 ± 0.2 1.1 ± 0.2 0.091
LDL [mmol/L] 2.2 ± 0.6 2.6 ± 0.8 0.052
ALT [U/L] 22.7 ± 6.0 24.9 ± 9.3 0.298
AST [U/L] 23.1 ± 5.0 21.8 ± 6.2 0.387
Scr [μmol/L] 67.6 ± 13.3 66.8 ± 20.1 0.857
FT4I [pmol/L] 14.6 ± 1.2 15.2 ± 1.5 0.083
CADS 0 27.8 ± 12.5 < 0.001
CAD — coronary artery disease; TC — total cholesterol; TG — tri­
glyceride; HDL — high density lipoprotein; LDL — low density lipo­
protein; ALT — alanine transaminase; AST — aspartate transamin­
ase; Scr — serum creatinine, FT4I — free thyroxine index; CADS — 
coronary artery disease score
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or chronic inflammatory disease(s), (iv) history 
of acute myocardial infarction, PCI or CABG, 
(v) autoimmune diseases, (vi) uncontrolled hy-
pertension, and (vii) malignant arrhythmias and 
valvular heart diseases.
Study process
All participants received coronary angiography 
(CAG) to determine whether they were healthy 
or had CAD. 6 CAD patients and 6 controls were 
selected and total RNAs were extracted from their 
venous blood samples for microarray analysis. The 
screened lncRNAs were then verified in the sec-
ond cohort, which included 30 normal individuals 
and 30 patients with different severities of CAD 
(as evaluated by SYNTAX scores and expressed 
as the coronary artery disease score [CADS]). 
The lncRNA with the best diagnostic value was 
selected as a potential biomarker. Finally, its di-
agnostic value was further assessed in the third 
independent cohort (control group, n = 115; and 
CAD group, n = 137).
Definition of CAD and collection of blood
Coronary artery disease was defined as the 
stenosis degree of any coronary artery ≥ 50%, di-
agnosed by CAG according to American College of 
Cardiology/American Heart Association Guidelines 
[24]. The stenosis degree of coronary artery was 
measured independently by two experienced cardi-
ology physicians by visual observation. In the control 
group, CAG showed no coronary atherosclerosis; 
treadmill exercise test (TET) presented negative 
results and emission computed tomography showed 
no myocardial ischemia, thus coronary microvas-
cular disease was excluded. Blood (2 mL) was col-
lected from the median cubital vein of patients, and 
stored in ethylenediaminetetraacetic acid (EDTA) 
anticoagulant vacutainers. The total RNA was then 
extracted as soon as possible.
Extraction of RNA and quantitative  
polymerase chain reaction (Q-PCR)
Total RNA was extracted from 1 mL of whole 
blood using the total RNA extraction kit (Bio-
tech, Beijing, China) strictly according to the 
manufacturer’s instructions. The extracted RNA 
was dissolved in RNase-free water. The concen-
tration and purity of RNA were determined by 
a NanoDrop 2000 instrument (Thermo Scientific, 
Waltham, MA, USA). The integrity of the RNA 
was detected with electrophoresis on the 1% 
formaldehyde-denaturing gel. Complementary 
DNA (cDNA) was synthesized by the Prime-
Script RT reagent kit (Takara Bio, Nojihigashi, 
Kusatsu, Japan) according to the manufacturer’s 
instructions. Q-PCR was conducted applying 
SYBR-Green Premix Ex Taq (Takara Bio, Nojihi-
gashi, Kusatsu, Japan) and monitored with an ABI 
PRISM 7500 Sequence Detection System (applied 
Biosystems, Life Technologies, Waltham, MA, 
USA). The relative expression levels of lncRNAs 
were determined by Q-PCR. The sequences of 
the primers used in Q-PCR are shown in Table 4.
Microarray expression profiling  
analysis of lncRNA
After selecting 6 participants from the control 
group and the CAD group respectively, we extract-
ed the total RNA of the whole blood for microarray 
analysis. The dephosphorylation, amplification and 
labeling of RNA were performed according to the 
manufacturer’s instructions. After purification, the 
labeled RNA was hybridized onto the microarray 
(Human lncRNA array, version 4.0, CapitalBio 
Corp., Beijing, China); with each array containing 
probes interrogating approximately 41,000 hu-
man lncRNAs. The microarray data of lncRNAs 
were analyzed with GeneSpring software V13.0 
(Agilent Technologies, Santa Clara, CA, USA). The 
threshold values of ≥ 2 and ≤ −2 fold change and 
a p < 0.05 of t-test were used to select differentially 
expressed lncRNAs.
Table 3. The clinical and demographic  
characteristics of the third cohort.
Control  
group
CAD  
group
P
Male gender 48 (41.7%) 73 (53.3%) 0.068
Age [years] 59.2 ± 8.7 61.4 ± 7.3 0.071
Hypertension 41 (35.7%) 59 (43.1%) 0.231
Diabetes mellitus 30 (26.1%) 49 (35.8%) 0.099
Smoker 30 (26.1%) 38 (27.7%) 0.769
HbA1c [%] 6.0 ± 0.9 6.1 ± 0.9 0.109
TC [mmol/L] 3.5 ± 1.3 4.1 ± 1.3 0.001
TG [mmol/L] 1.3 ± 0.5 1.9 ± 0.5 < 0.001
HDL [mmol/L] 1.4 ± 0.2 1.3 ± 0.3 0.040
LDL [mmol/L] 2.7 ± 0.6 3.1 ± 0.9 < 0.001
ALT [U/L] 31.7 ± 11.2 29.6 ± 9.4 0.102
AST [U/L] 28.2 ± 7.3 28.9 ± 9.2 0.522
Scr [μmol/L] 64.7 ± 14.9 63.6 ± 13.9 0.548
FT4I [pmol/L] 15.7 ± 1.7 15.3 ± 1.9 0.086
CAD — coronary artery disease; TC — total cholesterol; TG — tri­
glyceride; HDL — high density lipoprotein; LDL — low density lipo­
protein; ALT — alanine transaminase; AST — aspartate transamin­
ase; Scr — serum creatinine, FT4I — free thyroxine index
Figure 1. Heat map of long non­coding RNA (lncRNA) microarray profile. The expression of lncRNA is hierarchically 
clustered on the y­axis, and blood samples are hierarchically clustered on the x­axis. Expression level is presented 
in red and green, indicating upregulated and downregulated respectively. Numbers with A and B indicate control 
individuals and coronary artery disease patients.
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Statistical analysis
The data in this study were expressed as 
means ± standard deviations, medians (quartiles), 
or proportions when appropriate. In the scatterplot 
of the expression levels of lncRNA, the horizontal 
lines represent the medians. The categorical vari-
ables were verified using the c2 test, and continu-
ous variables were tested by Kolmogorov-Smirnov 
and Shapiro-Wilk tests to verify whether the data 
sets were normally distributed, and then data were 
analyzed by the two-tailed student t-test if they are 
normally distributed, or if non-normally distributed 
using Mann-Whitney U tests. The diagnostic value 
of lncRNA was evaluated by receiver operating 
characteristic (ROC) curve analysis. When area 
under the curve (AUC) = 0.5, the lncRNA was 
defined as having no diagnostic value. The cut-off 
value and corresponding sensitivity and specificity 
were elucidated according to ROC curve analysis. 
The correlations between the expression levels 
of lncRNAs and the CADS were analyzed by the 
Pearson correlation test. In order to calculate the 
odds ratio (OR), the relative expression levels of 
lncRNAs were multiplied by ten times to carry 
out logistic regression analysis. Then, OR and 
AUC were adjusted by introducing risk factors for 
CAD: smoking, hypertension, diabetes mellitus, 
total cholesterol (TC) and low-density lipoprotein 
(LDL). P < 0.05 was considered as statistically 
significant. All statistical analyses were conducted 
using SPSS 22.0 (SPSS Inc., Chicago, IL, USA).
Results
Expression profile of lncRNAs  
in the whole blood of CAD patients
Results of microarray analysis demonstrated 
significant differences in the expression profiles 
Table 4. Nucleotide sequences of primers used for quantitative polymerase chain reaction.
Target Forward Reverse Product length
ENST00000512246.1 CAGGGACACCAGTCCCTACG ACCAGGGGAACACCGATACC 99
TCONS_00023843 CAGTAAGGCCAGCTTTGCCA GGTTGGAACCAACAGAAGCCA 151
NR_028044.1 GTGCGCCATCAGGAGGAGAG CTCCTGACCACCAGCAAGAAA 113
TCONS_00029157 TGGTCGATGGCACAATTGCTA GCCAGGGTGAAATTTGCGGA 101
uc003wnt.1 CCTTGCCCTCCACCCATCTA GAGCTGGGGAGAAAAGCAGG 150
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of lncRNAs between these two groups (Fig. 1). 
31 lncRNAs were differentially expressed between 
the two groups, of which 25 lncRNAs were upregu-
lated and 6 were downregulated in CAD patients 
(Table 5). To identify the most clinically applicable 
biomarker, candidate biomarkers were selected in 
the upregulated lncRNAs utilizing strict screen-
ing criteria: p < 0.01, 5 lncRNAs were selected as 
candidate biomarkers: ENST00000512246.1 (re-
ferred to as Upperhand [25]), TCONS_00023843, 
NR_028044.1, TCONS_00029157 and uc003wnt.1 
(highlighted in Table 5).
Verification of the lncRNAs  
profile by Q-PCR
To validate the 5 selected candidate lncRNAs, 
Q-PCR was performed in an independent cohort 
consisting of 30 control individuals (CADS = 0, 
n = 30) and 30 CAD patients with different CADS 
(CADS 1–22, n = 10; CADS 23–32, n = 10; and 
CADS > 33, n = 10). The results are shown in 
Figure 2. Four of the five candidate biomarkers 
were significantly upregulated in the CAD group; 
there was a 2.6 fold change in the expression of 
Upperhand, and 2.4, 2.0, and 2.1 fold changes 
in the expression levels of TCONS_00023843, 
NR_028044.1, and TCONS_00029157, respec-
tively.
ROC curve analysis of the differentially  
expressed lncRNAs
To test the diagnostic values of Upper-
hand, TCONS_00023843, NR_028044.1 and 
TCONS_00029157 for CAD, ROC curve analyses 
were carried out (Fig. 2). The AUC of Upperhand 
was the largest: 0.804 (0.696–0.913, p < 0.001), 
and the cut-off value is 0.103. The AUC of 
TCONS_00023843 was 0.690 (0.556–0.824, p = 
= 0.011), and the cut-off value is 0.059. The AUCs 
and cut-off values were 0.739 (0.612–0.866, p = 
= 0.001) and 0.265, 0.769 (0.648–0.890, p < 0.001) 
and 0.217 for NR_028044.1 and TCONS_00029157, 
respectively. The sensitivity and specificity of each 
lncRNA were shown in Table 6. 
Correlations between lncRNAs  
and SYNTAX score for CAD
In clinical practice, SYNTAX score is always 
used to measure the severity of CAD, and on this 
basis, appropriate intervention methods are cho-
sen. In this study, correlations between  expres-
sion levels of candidate biomarkers and CADS 
were analyzed by the Pearson correlation test. 
Among the four chosen lncRNAs, Upperhand and 
TCONS_00029157 were correlated with the CADS. 
Based on the AUCs of the candidates and their cor-
relations with the CADS, Upperhand was chosen as 
the potential biomarker for the diagnosis of CAD.
Further clinical validation of the biomarker
The diagnostic value of Upperhand was veri-
fied in another independent cohort (control group, 
n = 115; and CAD group, n = 137). Results 
showed that the expression level of Upperhand 
was evidently upregulated in the CAD group, with 
Table 5. Differentially expressed lncRNAs  
between coronary artery disease patients  
and healthy individuals.
Upregulated lncRNAs P Fold change
uc003wnt.1 0.009 2.0
ENST00000454183.1 0.042 2.5
ENST00000553211.1 0.036 2.0
TCONS_00020626 0.029 2.1
XR_428751.1 0.034 3.7
TCONS_00015205 0.042 2.1
TCONS_00023843 0.001 2.1
XR_245754.1 0.028 2.1
ENST00000606037.1 0.019 2.0
ENST00000431705.1 0.049 2.2
TCONS_00024610 0.035 2.1
ENST00000416119.1 0.049 2.2
NR_028044.1 0.002 2.2
ENST00000539163.1 0.027 2.2
ENST00000439434.1 0.048 2.0
ENST00000583224.1 0.024 2.0
TCONS_00013397 0.045 2.1
ENST00000413810.1 0.011 2.3
ENST00000512246.1 0.001 2.1
TCONS_00029157 0.003 2.0
ENST00000497896.1 0.037 2.1
uc.342+ 0.011 2.3
XR_428826.1 0.025 2.0
XR_428901.1 0.029 2.0
ENST00000455229.1 0.045 2.8
Downregulated lncRNAs P Fold change
ENST00000451350.1 0.009 2.4
XR_426864.1 0.037 2.1
RNA33481 0.014 2.0
TCONS_00017757 0.010 2.5
TCONS_00018108 0.005 2.2
RNA147187 0.002 2.1
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a 2.2 fold change (Fig. 3). The ROC curve analysis 
presented an AUC of 0.728 (0.666–0.791, p < 0.001), 
with a sensitivity of 0.737 and specificity of 0.652; 
the crude OR and cut-off value was 1.64 (1.343–
2.002, p < 0.001) and 0.084. After introducing 
risk factors of CAD (diabetes mellitus, smoking, 
hypertension, TC and LDL), the AUC slightly in-
creased to 0.790 (0.735–0.846, p < 0.001), with the 
sensitivity of 0.65 and specificity of 0.835; the adjust-
ed OR of 1.76 (1.402–2.210, p < 0.001) and cut-off 
value of 0.584. The results indicated that Upper-
hand could serve as a diagnostic biomarker of CAD. 
Expression of biomarker in different  
genders and ages
To investigate the expression level of Up-
perhand in different gender and age groups, the 
two groups in the third cohort was further divided 
according to gender and age (cut-off: 60 years old), 
respectively. As shown in Table 7, the distribution 
of Upperhand in different gender and age groups 
presented no statistically significant differences.
Improvement in the diagnostic value
To improve the diagnostic value of the biomarker, 
TCONS_00029157 was introduced. As shown in 
the Figure 3, TCONS_00029157 was significantly 
upregulated in the CAD group, with a change of 
1.8 fold. Upperhand and TCONS_00029157 were 
combined, and the combination as a new biomarker 
was tested by ROC analysis. The results showed 
AUC was 0.774 (0.716–0.831, p < 0.001), and 
the sensitivity was 0.847 and specificity was 0.6, 
respectively; the cut-off value was 0.395. After in-
troducing the risk factors for CAD (smoking, hyper-
tension, diabetes mellitus, LDL and TC) the AUC 
slightly increased to 0.846 (0.798–0.893, p < 0.001), 
the sensitivity was 0.723 and the specificity was 
0.817; the cut-off value was 0.546. This implied 
that, compared with Upperhand, the combination of 
Figure 2. Expression levels of selected long non­coding RNA (lncRNA) quantified by quantitative polymerase 
chain reaction. Panels A–D indicate the expression levels of Upperhand, TCONS_00023843, NR_028044.1 and 
TCONS_00029157 in the control group and coronary artery disease group, *p < 0.05; Panels E–H indicate the receiver 
operating characteristic curve analyses of the above mentioned lncRNAs for the diagnoses of coronary artery disease.
Table 6. The sensitivity and specificity of the selected long non­coding RNA (lncRNA).
AUC 95% CI Sensitivity Specificity P
ENST00000512246.1 0.804 0.696–0.913 0.833 0.7 < 0.001
TCONS_00023843 0.69 0.556–0.824 0.767 0.567 0.011
NR_028044.1 0.739 0.612–0.866 0.6 0.833 0.001
TCONS_00029157 0.769 0.648–0.890 0.667 0.833 < 0.001
AUC — area under the curve; CI — confidence interval
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Figure 3. Expression levels of Upperhand. Panels A and C indicate the expression levels of Upperhand and Upper­
hand combined with TCONS_00029157 in the control group and the coronary artery disease group, respectively, 
*p < 0.05; Panel B indicates the ROC curve analyses of Upperhand and Upperhand with risk factors for the diagnosis 
of coronary artery disease; Panel D indicates the receiver operating characteristic curve analyses of the combination 
long non­coding RNA (lncRNA).
Table 7. The expression levels of Upperhand in populations with different gender and age.
Variables Amount Control group 
relative expression
P Amount CAD group 
relative expression
P
Gender:
Male 48 0.05 (0.02,0.16)
0.671
73 0.16 (0.07,0.31)
0.806
Female 67 0.06 (0.03,0.15) 64 0.14 (0.07,0.33)
Age [years]:
> 60 52 0.06 (0.03,0.14)
0.507
74 0.18 (0.09,0.35)
0.066
≤ 60 63 0.05 (0.03,0.17) 63 0.14 (0.06,0.29)
CAD — coronary artery disease
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Upperhand and TCONS_00029157 as a biomarker 
has a higher diagnostic value for CAD. 
Discussion
Due to its high morbidity and mortality world-
wide, CAD is a serious threat to human health. The 
current diagnostic methods for CAD are classified 
into two types, invasive and non-invasive. The 
non-invasive examinations include electrocardio-
gram (ECG), TET, Holter monitoring and coronary 
computed tomography angiography (CTA). Among 
them, ECG presents poor sensitivity and specific-
ity in the diagnosis of CAD. Holter monitoring can 
diagnose CAD only when it captures the dynamic 
changes during the onset of angina. Many elderly 
people and patients with limited physical activi-
ties are unable to complete TET; moreover, the 
induction of myocardial ischemia may lead to the 
rupture of unstable plaques in a small number of 
patients, causing adverse cardiac events. In addi-
tion, coronary CTA has a relatively high cost. Inva-
sive examinations include CAG and intravascular 
ultrasound (IVUS). CAG is the gold standard for 
the diagnosis of CAD; IVUS, in which a miniature 
ultrasound probe is sent into the vessel lumen to 
obtain a tomographic scan andcan accurately and 
intuitively determine residual stenosis and guide 
stenting [26]. In China, however, many low-income 
families cannot easily afford these examinations, 
and some patients with mild symptoms and con-
servative ideologies are not willing to do these 
invasive examinations. Therefore, a clinical exami-
nation with low cost, high accuracy and conveni-
ence is needed to facilitate the detection of CAD.
Because of the convenient sampling and low 
cost, hematological markers play an important role in 
the diagnosis of many diseases. A number of studies 
indicate that miRNAs are involved in the occurrence 
and development of various cardiovascular diseases 
including arrhythmia, hypertension, coronary ar-
tery calcification, myocardial hypertrophy and CAD 
[27–32]. LncRNAs could regulate gene expression 
by interacting with miRNAs [33, 34]. Compared 
with miRNAs, the mechanisms of lncRNAs in gene 
regulation are more complex, and the regulatory 
modes are more flexible [35]. Furthermore, multiple 
studies have shown that lncRNAs in body fluid have 
excellent stability [36]. Therefore, it was speculated 
that, compared with miRNAs, 1ncRNAs may be more 
suitable in serving as diagnostic biomarkers.
The result of gene ontology enrichment analy-
sis suggests that Upperhand is correlated with LDL 
receptor activity, vascular smooth muscle contrac-
tion and other cellular processes. It is well known 
that these processes all play important roles in the 
progression of CAD. Therefore, it was speculated 
that Upperhand may be involved in the progression 
of CAD through these biological processes.
At present, many methods are used to diag-
nose CAD besides CAG, such as ECG, Holter, TET 
and CTA. The sensitivity and specificity of ECG are 
0.414 and 0.675 [37]. The sensitivity and specificity 
of Holter are 0.649 and 0.894 [38]. The sensitivity 
and specificity of TET are 0.650 and 0.580 [39]. 
The sensitivity and specificity of CTA are 0.930 
and 0.860 [39]. The sensitivity and specificity of 
Upperhand are 0.737 and 0.652; when Upperhand 
was combined with TCONS_00029157, sensitivity 
and specificity of the combined biomarker were 
0.847 and 0.6, respectively. Based on this com-
parison, it was thought that the diagnostic value 
of Upperhand and the combination of Upperhand 
and TCONS_00029157 are greater than ECG and 
TET, slightly lower than Holter, while significantly 
lower than CTA. However, when considering the 
convenience and cost of diagnostic methods, it was 
believed that the biomarker will improve the situa-
tion of the diagnosis of CAD significantly. Further-
more, the expression characteristics of Upperhand 
showed no differences between populations with 
different genders and ages. These findings suggest 
that Upperhand, indeed, has the potential to serve 
as a diagnostic biomarker of CAD. 
Limitations of the study
This study was a single-center study, with 
a high geographic concentration of the subjects. 
Therefore, the populations of other regions and 
countries remain to be identified in determining 
whether they have  similar lncRNAs expression 
features. The lncRNAs in this study are mainly 
from peripheral blood mononuclear cells, so their 
biological link with CAD is rather weak. Mean-
while, there are differences between CAD and 
control individuals in pharmacotherapy, and that 
could also have influenced the results.
Conclusions
To sum up, this study investigates the lncRNA 
profile in peripheral blood of CAD patients, de-
termines its correlation with the severity of CAD 
and tests the potential of lncRNA as a diagnostic 
biomarker of CAD. The biomarker identified in this 
study (Upperhand) can be tested using peripheral 
blood at a relatively low cost, yet  specificity and 
sensitivity are relatively high, and the diagnos-
www.cardiologyjournal.org 401
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tic value is slightly increased after introducing 
TCONS_00029157, making Upperhand a powerful 
tool in the diagnosis of CAD. 
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